Flagship · Bulletin

Macro rationale

Macro digest keeps NEUTRAL: VIX 15.84 (-15% vs 200d) and HY OAS 2.70 below its SMA signal loose conditions, while QQQ extension (+13.72% vs 200d) plus the confirmed complacency gap (NFCI -0.516, NAAIM 84.69, NFP +57K) and the live Hormuz war argue for caution rather than risk-on. 2s10s 0.36 not inverted. This is a scope-locked, event-driven patch, not a regime rebalance — the regime read is unchanged from last run. The only structural action is the mandatory §2/§3 biology pillar-floor cure (biology at 10.00% on entry-weight, below floor on the over-bought normalized basis). Cash moves 12.08→9.08% solely to fund the named floor-cure open (ARGX) — a valid named cause — and stays comfortably inside the NEUTRAL 5-15% base band. The regime's cash-tilt toward the band top is deferred to the next full deep run, where non-scope-locked cash management is permitted.

Thesis

Scope-locked, event-driven patch. The binding action is the mandatory §2/§3 biology pillar-floor cure: biology sits at 10.00% (LLY 7% + VRTX 3%) on entry-weight, below floor on the over-bought normalized basis. Rather than pile more into the two existing names, I cure the floor AND satisfy the 18-position minimum by opening ARGX — the best durable long-run openable name in scope (score 69): a self-funded, high-margin, net-cash Vyvgart autoimmune franchise with a named, accelerating catalyst set (FDA all-serotype gMG expansion, CIDP approval, MMN/SjD label expansions) and a $6B→$16B peak-sales runway. This broadens a fragile two-name biology pillar to three durable legs (LLY 7% / VRTX 3% / ARGX 3% = 13%, comfortably over the 10% floor), adds a non-US ADR helping the 15% floor, and brings the book from 17 to 18 (into the band). NVO is skipped (re-entry cooldown 33d, redundant with LLY, no new flow — price recovery is not a flow change). ILMN/RGEN/SDGR score lower and are less durable. Funded 3pp from cash (12.08→9.08%, mid NEUTRAL band) — a named open cause. Every out-of-scope name holds verbatim at delta 0 per the scope lock.

Reflection

Scope-locked biology pillar-floor cure — opening ARGX as a durable third biology leg to clear the 10% floor and bring the book to 18. No flow shift elsewhere.

The 18-position schema minimum finally forced the biology open my last several reflections kept deferring to 'the next deep run' — and the scope lock (biology-only) actually made the decision for me. ARGX is the cleanest durable openable name: commercial-stage, self-funded, real Vyvgart revenue inflecting across indications, not a story stock. Tension I hold: it's a re-entry ~40d after a prior drop, but it carries no cooldown flag and the FDA all-serotype expansion + CIDP approval are genuinely NEW named flow since then. I deliberately sized it at the 3% minimum rather than larger because the

Positions (18)

• MUMicron Technologycompute

  hold3.54%79
  flow steadyconf

  Funder

  US HBM3E/HBM4 supplier in a capacity-disciplined memory cycle; 84.6% GM, fcf+. 16 Strategic Customer Agreements covering ~20% DRAM / ~1/3 NAND through 2030 (~$100B contracted); ~$725B 2026 hyperscaler capex; Goldman names memory a top-3 AI-infra beneficiary.

  Unwind

  DRAM/NAND spot-price collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; SCA book erosion.

  Catalyst

  Next FQ print / HBM4 qualification cadence.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold7.76%83
  flow steadyconf

  Funder

  Leading-edge foundry monopoly (<3nm), >50% GM, prodigious FCF, disciplined capex — routes the world's AI silicon. Goldman's $920B-$1.4T 2027 AI-capex forecast names TSMC explicitly; CHIPS $6.6B Arizona disbursement locked.

  Unwind

  Competitor 3nm yield convergence; GM compression below 50%; a genuine AI-capex cut (not KOSPI-margin liquidation noise).

  Catalyst

  Monthly sales / Q2 earnings.

• NVDANVIDIAcompute

  hold2.89%72
  flow steadyconf

  Funder

  CUDA/accelerator software moat, ~75% GM, fortress balance sheet. ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B); Stargate $500B JV.

  Unwind

  Hyperscaler ASIC displacement of merchant GPU; GM break below ~70%; two consecutive sub-20% data-center revenue quarters. Held at reduced weight through score drift (72); no add until >80.

  Catalyst

  Next earnings data-center growth print.

• ASMLASML Holdingcompute

  hold3.68%64
  flow steadyconf

  Funder

  EUV lithography monopoly — the single most irreplaceable tool in advanced semis, ~50% GM, multi-year backlog, no commercial-scale alternative. Norway GPFG holds; Coatue/Third Point added Q1; TSMC/Samsung/Intel EUV+High-NA orderbook backstops cash flow.

  Unwind

  Book-to-bill breaks below threshold at Q2 results; a commercial EUV alternative; large order cancellations. Score 64 — trim discipline engages only below 60.

  Catalyst

  July 15 Q2 bookings.

• AVGOBroadcomcompute

  hold2.25%62
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) + VMware software, huge FCF, $7B+ buyback, serial dividend grower. GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW ASIC contracts; Apple 10-yr partnership; OpenAI custom-chip win.

  Unwind

  ASIC share loss; AI-segment bookings disappoint next print; FCF/buyback break. Score 62, 2pts above broken threshold — hard review if <60.

  Catalyst

  Next earnings custom-chip run-rate vs ~$25B threshold.

• ANETArista Networkscompute

  hold1.93%67
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise, share-gainer since 2004, ~65% GM, net cash, single-image EOS software moat, Ullal-led capital discipline. Microsoft & Meta named largest customers funding 35% YoY growth; Morgan Stanley PT $190 OW.

  Unwind

  NVDA Spectrum-X displacing Arista in a major footprint; forward P/E >45x with growth decel; hyperscaler in-house switching pivot.

  Catalyst

  Next earnings.

• FNcompute

  hold1.37%63
  flow softeningconf

  Funder

  Optical transceiver/packaging manufacturer interconnecting hyperscaler AI clusters; capital-light, debt-free, extracts hyperscaler capex without silicon R&D risk. AWS dominant customer drove ~36% YoY growth; 800G/1.6T demand from NVDA/AMD clusters.

  Unwind

  P/E >35x during decelerating growth; Datacom sequential-growth break; GM compression. Second-hyperscaler 800G design-win still unverified.

  Catalyst

  Next earnings Datacom sequential growth.

• CCJCamecoenergy

  hold8.13%65
  flow steadyconf

  Funder

  Tail-risk hedge slot: tier-1 Saskatchewan uranium franchise + Westinghouse 49% JV with Brookfield. DOE $17.5B AP1000 loan commitment, Kazatomprom 8Mlb output cut sustaining a structural deficit, contract book $60+/lb vs ~$93 term market.

  Unwind

  Uranium spot/term price collapse; contract-book erosion; DOE loan program withdrawal. Score drift (65) alone is not a trim trigger — thematic tailwind intact.

  Catalyst

  Term-price prints / next earnings.

• GEVGE Vernovaenergy

  hold7.51%63
  flow steadyconf

  Funder

  Gas-turbine + grid franchise with pricing power — ~$263B backlog, 100GW turbine backlog, 10-20% price realization, 12.8% net margin, $3.7B FCF. Norway GPFG added post-spin; Oracle $90-95B FY27 + Alphabet $80B capex pull-through.

  Unwind

  Backlog cancellation or wind-loss deterioration; EV/EBITDA breaching ~25x exit ceiling; a hyperscaler power-capex cut.

  Catalyst

  Next earnings / backlog update.

• SCCOSouthern Copperenergy

  hold7.53%63
  flow steadyconf

  Funder

  Tail-risk hedge slot: lowest-cost copper producer, vast reserves, fat margins, large dividend. Copper supply deficit ~320k tonnes 2026, record Q1 NI $1.58B, AI/data-center ~30% of new copper demand by 2030 (BloombergNEF); Grupo Mexico owners.

  Unwind

  Copper price collapse below entry thesis; Peru/Mexico permitting shock; AI/grid demand thesis break.

  Catalyst

  Copper price / next earnings.

• MPMP Materialsenergy

  hold4.48%
  flow softeningconf

  Funder

  Only scaled US rare-earth + magnet producer; DoD $400M Series A preferred + $150M loan + 10-yr $110/kg NdPr price floor + 10-yr magnet offtake for the 10X facility — a government-backstopped moat vs China's 98% magnet control.

  Unwind

  FCF stays negative through the magnet ramp; China blacklist chokes processing-tech access materially; 10X construction slips; DoD backstop withdrawn.

  Catalyst

  Magnet-segment FCF inflection / 10X construction milestones.

• NEMNewmont Corporationenergy

  hold5.43%89
  flow softeningconf

  Funder

  Tail-risk equity hedge (§5.3/10.2): largest gold producer, tier-1 long-life assets, strong post-Newcrest FCF and dividend, $3.2B net cash Q1. Red Chris JV secured $500M Canadian-government backing; central-bank gold accumulation.

  Unwind

  Gold sustained bear market driven by rising real yields (Fed-credibility repricing, not stagflation) evaporating the tail bid; cost inflation; FCF break.

  Catalyst

  Gold price inflection / next earnings.

• KTOSKratos Defensedefense

  hold9.25%
  flow steadyconf

  Funder

  Tactical drones (XQ-58 Valkyrie), hypersonics, turbine engines — DAWG-adjacent defense-tech. DoD MACH-TB 2.0 $1.45B IDIQ, Project Helios $68.3M, USMC Valkyrie mods; $190M Rocket Lab HASTE validation; FY27 DAWG ~$54.6B line; UK £5B drone program; ARK accumulation.

  Unwind

  FY27 DAWG appropriations cut; revenue-inflection/margin-firming fails to confirm; quarterly contract flow stalls.

  Catalyst

  DAWG appropriations / next earnings revenue inflection.

• HEIHEICOdefense

  hold9.24%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR, disciplined serial acquirer ($1B+/yr). Record Q2 (net income +49% YoY, sales $1.375B +25%, ETG op-income +56%); NDAA mandatory funding + commercial MRO.

  Unwind

  Forward P/E >50x without accelerating growth; organic growth below ~6% floor; a value-destroying acquisition or capital-allocation break.

  Catalyst

  Next earnings organic-growth trajectory.

• PSNdefense

  hold2.91%50
  flow softeningconf

  Funder

  C5ISR/cyber government-services prime, sticky multi-year IDIQ backlog: MDA SHIELD $151B-ceiling IDIQ, DTRA cyber $137M, USAF MATOC $15B, Navy WEXMAC $10B, plus $1.1-1.4B Blatnik Bridge win and Qatar Lusail contract.

  Unwind

  Score already 50 (below 60 floor); SHIELD task-order conversion continues to fail; book-to-bill deteriorates further. Weak but out-of-scope this patch — hold; deep-run review pending.

  Catalyst

  SHIELD task-order conversion / book-to-bill.

• LLYEli Lillybiology

  hold4.70%70
  flow steadyconf

  Funder

  Premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise (~60% US GLP-1 share, $12B+ quarterly sales) + oral orforglipron (Foundayo) FDA-approved Apr 2026 + retatrutide Ph3 (~70lb loss); 82.9% margin, fcf+, $27B manufacturing expansion.

  Unwind

  10pt US GLP-1 share loss to NVO; retatrutide Ph3 failure; margin/FCF deterioration; a CMS Part-D/IRA pricing shock.

  Catalyst

  Retatrutide Ph3 / CMS pricing timeline.

• VRTXVertex Pharmaceuticalsbiology

  hold2.30%76
  flow steadyconf

  Funder

  Durable biology compounder: cystic-fibrosis monopoly (Trikafta) cash engine, self-funded, 86.8% GM, $3.71B TTM FCF, fortress balance sheet. Tailwind: Casgevy commercializing across 12+ jurisdictions (Medicare Cell & Gene Access Model) + $10B Crinetics deal diversifying beyond CF.

  Unwind

  Trikafta patent/competitive erosion breaking the CF cash engine; Casgevy reimbursement stalls; Crinetics integration destroys FCF; margin/FCF deterioration.

  Catalyst

  Crinetics integration / Casgevy reimbursement ramp.

• ARGXargenxbiology

  hold3.00%69
  flow acceleratingconf

  Funder

  argenx — Vyvgart/Vyvgart Hytrulo (efgartigimod) autoimmune franchise; self-funded commercial-stage biotech, high-margin, net cash, a durable 20-30yr FcRn franchise. Named flow: FDA expanded gMG approval to all serotypes incl. seronegative (5/28, ~18% TAM expansion); CIDP approval + MMN/SjD label expansions inflecting; peak-sales trajectory $6B→$16B by 2036; GPFG/large AM holders. Belgian ADR adds

  Unwind

  CIDP/MMN/SjD label-expansion trials fail or competitive FcRn entrants (UCB rozanolixizumab, J&J nipocalimab) erode share; revenue growth decel with margin break; pipeline setback.

  Catalyst

  CIDP/SjD/MMN label-expansion readouts through 2026; next quarterly Vyvgart revenue print.

Warnings

• stale_policy guard: ARGX open → hold (delta zeroed)
• §2 cap re-applied after pillar tilt: MU
• §2 cap re-applied after pillar tilt: NVDA
• §2 cap re-applied after pillar tilt: AVGO
• §2 cap re-applied after pillar tilt: ANET
• §2 cap re-applied after pillar tilt: FN
• §2 cap re-applied after pillar tilt: GEV
• §2 cap re-applied after pillar tilt: MP
• §2 cap re-applied after pillar tilt: NEM
• §2 cap re-applied after pillar tilt: KTOS
• §2 cap re-applied after pillar tilt: HEI
• §2 cap re-applied after pillar tilt: PSN
• §2 cap re-applied after pillar tilt: LLY
• §2 cap re-applied after pillar tilt: VRTX
• §6.6 entry floor: ARGX open dragged to 2.31pp by renormalization (model intent 3pp ≥ 3pp) → floored at 3pp, not left a token position
• ledger stale (ledger over-bought (cash -33.37% of NAV)) — rebalance diffed against intent

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.